A	O
novel	O
LSD1	O
inhibitor	O
NCD38	O
ameliorates	O
MDS	S-DISEASE
-	O
related	O
leukemia	S-DISEASE
with	O
complex	O
karyotype	O
by	O
attenuating	O
leukemia	S-DISEASE
programs	O
via	O
activating	O
super	O
-	O
enhancers	O
.	O


Lysine	O
-	O
specific	O
demethylase	O
1	O
(	O
LSD1	O
)	O
regulates	O
gene	O
expression	O
by	O
affecting	O
histone	O
modifications	O
and	O
is	O
a	O
promising	O
target	O
for	O
acute	B-DISEASE
myeloid	I-DISEASE
leukemia	E-DISEASE
(	O
AML	S-DISEASE
)	O
with	O
specific	O
genetic	O
abnormalities	O
.	O


Novel	O
LSD1	O
inhibitors	O
,	O
NCD25	O
and	O
NCD38	O
,	O
inhibited	O
growth	O
of	O
MLL	B-DISEASE
-	I-DISEASE
AF9	I-DISEASE
leukemia	E-DISEASE
as	O
well	O
as	O
erythroleukemia	S-DISEASE
,	O
megakaryoblastic	B-DISEASE
leukemia	E-DISEASE
and	O
myelodysplastic	B-DISEASE
syndromes	E-DISEASE
(	O
MDSs	S-DISEASE
)	O
overt	O
leukemia	O
cells	O
in	O
the	O
concentration	O
range	O
that	O
normal	O
hematopoiesis	O
was	O
spared	O
.	O


NCD25	O
and	O
NCD38	O
invoked	O
the	O
myeloid	O
development	O
programs	O
,	O
hindered	O
the	O
MDS	S-DISEASE
and	O
AML	S-DISEASE
oncogenic	O
programs	O
,	O
and	O
commonly	O
upregulated	O
62	O
genes	O
in	O
several	O
leukemia	O
cells	O
.	O


NCD38	O
elevated	O
H3K27ac	O
level	O
on	O
enhancers	O
of	O
these	O
LSD1	O
signature	O
genes	O
and	O
newly	O
activated	O
~	O
500	O
super	O
-	O
enhancers	O
.	O


Upregulated	O
genes	O
with	O
super	O
-	O
enhancer	O
activation	O
in	O
erythroleukemia	O
cells	O
were	O
enriched	O
in	O
leukocyte	O
differentiation	O
.	O


Eleven	O
genes	O
including	O
GFI1	O
and	O
ERG	O
,	O
but	O
not	O
CEBPA	O
,	O
were	O
identified	O
as	O
the	O
LSD1	O
signature	O
with	O
super	O
-	O
enhancer	O
activation	O
.	O


Super	O
-	O
enhancers	O
of	O
these	O
genes	O
were	O
activated	O
prior	O
to	O
induction	O
of	O
the	O
transcripts	O
and	O
myeloid	O
differentiation	O
.	O


Depletion	O
of	O
GFI1	O
attenuated	O
myeloid	O
differentiation	O
by	O
NCD38	O
.	O


Finally	O
,	O
a	O
single	O
administration	O
of	O
NCD38	O
causes	O
the	O
in	O
vivo	O
eradication	O
of	O
primary	O
MDS	O
-	O
related	O
leukemia	O
cells	O
with	O
a	O
complex	O
karyotype	O
.	O


Together	O
,	O
NCD38	O
derepresses	O
super	O
-	O
enhancers	O
of	O
hematopoietic	O
regulators	O
that	O
are	O
silenced	O
abnormally	O
by	O
LSD1	O
,	O
attenuates	O
leukemogenic	O
programs	O
and	O
consequently	O
exerts	O
anti	O
-	O
leukemic	O
effect	O
against	O
MDS	S-DISEASE
-	O
related	O
leukemia	S-DISEASE
with	O
adverse	O
outcome	O
.	O
